SARS-CoV-2 and Influenza A virus: Dual diagnostics and vaccines

Saied, AbdulRahman A; Dhawan, Manish; Choudhary, Priyanka; Choudhary, Om Prakash

doi:10.1016/j.ijsu.2022.106653

Cited by 3 publications

(3 citation statements)

References 18 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BrNAbs with long CDR H3 are promising candidates for prophylaxis and antibody‐based immunotherapy. 122 , 123 Other viruses, such as influenza or SARS‐CoV‐2, 124 may benefit from a similar approach, eliminating the need for expensive annual vaccinations or offering a therapeutic response to prevent pandemic outbreaks. 125 The TcB platform for producing hIgs is still relatively new, and products are only now making their way into clinical trials.…”

Section: Discussionmentioning

confidence: 99%

Transchromosomic bovines‐derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS‐CoV‐2, MERS‐CoV, Ebola, Zika, HIV‐1, and influenza A virus

Saied

Nascimento

Rangel

et al. 2022

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Historically, passive immunotherapy is an approved approach for protecting and treating humans against various diseases when other alternative therapeutic options are unavailable. Human polyclonal antibodies (hpAbs) can be made from convalescent human donor serum, although it is considered limited due to pandemics and the urgent requirement. Additionally, polyclonal antibodies (pAbs) could be generated from animals, but they may cause severe immunoreactivity and, once "humanized," may have lower neutralization efficiency. Transchromosomic bovines (TcBs) have been developed to address these concerns by creating robust neutralizing hpAbs, which are useful in preventing and/or curing human infections in response to hyperimmunization with vaccines holding adjuvants and/or immune stimulators over an extensive period. Unlike other animal‐derived pAbs, potent hpAbs could be promptly produced from TcB in large amounts to assist against an outbreak scenario. Some of these highly efficacious TcB‐derived antibodies have already neutralized and blocked diseases in clinical studies. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has numerous variants classified into variants of concern (VOCs), variants of interest (VOIs), and variants under monitoring. Although these variants possess different mutations, such as N501Y, E484K, K417N, K417T, L452R, T478K, and P681R, SAB‐185 has shown broad neutralizing activity against VOCs, such as Alpha, Beta, Gamma, Delta, and Omicron variants, and VOIs, such as Epsilon, Iota, Kappa, and Lambda variants. This article highlights recent developments in the field of bovine‐derived biotherapeutics, which are seen as a practical platform for developing safe and effective antivirals with broad activity, particularly considering emerging viral infections such as SARS‐CoV‐2, Ebola, Middle East respiratory syndrome coronavirus, Zika, human immunodeficiency virus type 1, and influenza A virus. Antibodies in the bovine serum or colostrum, which have been proved to be more protective than their human counterparts, are also reviewed.

show abstract

Section: Discussionmentioning

confidence: 99%

Transchromosomic bovines‐derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS‐CoV‐2, MERS‐CoV, Ebola, Zika, HIV‐1, and influenza A virus

Saied

Nascimento

Rangel

et al. 2022

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Influenza virus and SARS-CoV-2 virus are two important pathogen causing respiratory tract infection, both viruses are highly contagious with high rates of mutation, which makes clinical antiviral treatment difficult ( 18 ). Chinese herbal extracts have direct or indirect antiviral effects on different periods of viral infection by targeting key steps in the viral replication cycle and key cellular components of the host defense system ( 18 , 19 ). For example, pentagalloyl glucose extracted from the plant emblica can inhibit the release of virus particles ( 20 ), and dendrobine extracted from dendrobium interferes with early virus replication ( 21 ).…”

Section: Introductionmentioning

confidence: 99%

Plant-derived Ren's oligopeptide has antiviral effects on influenza virus and SARS-CoV-2

Chen

Huang²,

Ren³

et al. 2023

Front. Vet. Sci.

View full text Add to dashboard Cite

Influenza virus and SARS-CoV-2 virus are two important viruses that cause respiratory tract diseases. The high-frequency mutation of the two types of viruses leads to failure of the durable immune protection of vaccines, meanwhile it also poses continuous challenges to the development of antiviral drugs. Traditional Chinese medicine contains large number of biologically active compounds, and some of them contain broad-spectrum antiviral ingredients. In this study, we extracted antiviral active ingredients from medicinal and edible plants by biotransformation and enzymatic hydrolysis as a drug, and we named this drug Ren's oligopeptide. Further, we analyzed the antiviral activity of this drug and found that Ren's oligopeptide could inhibit the replication of influenza virus and SARS-CoV-2 virus with high anti-virus activities. In vitro experiments showed that the antiviral activity of the Ren's oligopeptide mainly targets the replication process after virus enters the cell. Therefore, Ren's oligopeptide is a promising drug against influenza and COVID-19.

show abstract

“…Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is novel, no one has pre-existing immunity to it. A peculiar trend of SARS-CoV-2 infection has been observed in adults or patients with a weak or compromised immune system, leading to influenza-like symptoms, namely cough, fever, myalgia or fatigue 1 , 2 , and death in severe cases (like acute respiratory distress syndrome, pneumonia) around the globe 3 . To everyone’s surprise, no such severe symptoms or need of hospitalization has been reported in children although children under 5 years of age have a less-developed immune system compared to adults and are more vulnerable to diseases like influenza or common cold.…”

mentioning

confidence: 99%

Variability of severe acute respiratory syndrome coronavirus 2 infection in children and adults

Verma

Dhawan

Saied

et al. 2023

International Journal of Surgery

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2 and Influenza A virus: Dual diagnostics and vaccines

Cited by 3 publications

References 18 publications

Transchromosomic bovines‐derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS‐CoV‐2, MERS‐CoV, Ebola, Zika, HIV‐1, and influenza A virus

Transchromosomic bovines‐derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS‐CoV‐2, MERS‐CoV, Ebola, Zika, HIV‐1, and influenza A virus

Plant-derived Ren's oligopeptide has antiviral effects on influenza virus and SARS-CoV-2

Variability of severe acute respiratory syndrome coronavirus 2 infection in children and adults

Contact Info

Product

Resources

About

SARS-CoV-2 and Influenza A virus: Dual diagnostics and vaccines

Cited by 3 publications

References 18 publications

Transchromosomic bovines‐derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS‐CoV‐2, MERS‐CoV, Ebola, Zika, HIV‐1, and influenza A virus

Transchromosomic bovines‐derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS‐CoV‐2, MERS‐CoV, Ebola, Zika, HIV‐1, and influenza A virus

Plant-derived Ren's oligopeptide has antiviral effects on influenza virus and SARS-CoV-2

Variability of severe acute respiratory syndrome coronavirus 2 infection in children and adults

Contact Info

Product

Resources

About

Variability of severe acute respiratory syndrome coronavirus 2 infection in children and adults